Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies
Merck & Co has put the brakes on enrolment into two Phase III trials of Keytruda in multiple myeloma to allow it to investigate more deaths in the groups receiving the anti-PD1 product.
You may also be interested in...
Deciphering US FDA’s Keytruda Safety Announcement
Safety notice for Merck's Keytruda in multiple myeloma had some notable elements – from what comes next to who delivered the message.
Merck & Co. Strengthening Its Strong Position In Immuno-Oncology
Additional data presented at ASCO support earlier use of Keytruda in key settings like first-line lung and bladder cancers and approval in new indications like triple-negative breast and gastric cancers. Competitor setbacks also clear the stage for Merck.
Oncology’s Hold Over The Pharma Pipeline Increases As Growth Slows
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.